Say what? Compassionate use program? What compassionate use program?
It’s no secret that the average biotech company is no great fan of compassionate use requests for their experimental drugs. They can be expensive to satisfy and present a potential threat if the drug backfires with an unexpected side effect.
So it’s no great surprise that the typical biotech company doesn’t provide a simple online gateway for patients desperate to gain access to their experimental therapies outside of trials. And if the 21st Century Cures Act ever passes, that could present an issue in need of quick resolution.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.